Ocugen Reports Positive Phase 2 Gene Therapy Data

Ocugen has announced topline 12-month data from its Phase 2 ArMaDa clinical trial evaluating OCU410, a modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration. The results indicate that the optimal dose intended for Phase 3 demonstrated a statistically significant reduction in lesion growth by 31% compared to the control group. This positive outcome suggests OCU410 holds promise as a potential treatment for this debilitating eye condition, paving the way for further clinical development.